Beam Therapeutics, a company focused on genome editing, is in a strange situation.
The firm’s stock price has roughly quadrupled since the fall, and not because of pivotal data or an affirmational partnership but rather because of a broad and quite likely temporary boom for companies involved in editing DNA. But unlike some of its contemporaries, Beam isn’t letting its moment go to waste.
About the Author Reprints
